You are here

PHOSPHORYLATABLE MONOCLONAL ANTIBODIES FOR TUMOR THERAPY

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 2R44CA086568-02A1
Agency Tracking Number: CA086568
Amount: $1,270,828.00
Phase: Phase II
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Timeline
Solicitation Year: N/A
Award Year: 2002
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
PBL BIOMEDICAL LABORATORIES 131 ETHEL RD W, STE 6
PISCATAWAY, NJ 08854-5900, NJ 08854
United States
DUNS: N/A
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 WILLIAM CLARK
 (732) 777-9123
 BCLARK@PBLBIO.COM
Business Contact
 ROBERT PESTKA
Phone: (732) 777-9123
Email: RP@PBLBIO.COM
Research Institution
N/A
Abstract

DESCRIPTION (provided by applicant): The long-term objectives of this proposal are to develop an efficient, effective, safe, convenient and economical
monoclonal antibodies (MAbs) labeled with radioactive phosphate for therapy of
cancers. Many chemical labeling procedures are currently used, but all these
methods inactivate the antibodies to a significant extent (20 - 70 percent).
The technology described in this proposal avoids this serious problem and has
many advantages over the current methods. The specific aims of this proposal,
designed to achieve the objectives and demonstrate the extraordinary advantages
of this technology over other procedures, are: 1) Examine the in vivo
distribution of [32P]radiolabeled MAbs in athymic mice bearing human tumors; 2)
Evaluate the efficacy of MAbs labeled with this new technology compared to a
common chemical method in arresting tumor growth; 3) Develop reagent,
production, and finished product assays and protocols in preparation for
clinical trials; 4) Use the new technology to develop one additional MAb to
broaden the range of cancers targeted by this new procedure from
adenocarcinomas in general (colon, breast, ovarian, lung, pancreatic, prostate
cancers), to malignant melanoma. This work should benefit the larger population
of patients and be useful to many companies developing MAbs for the treatment
and detection of cancers.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government